Oregon 2023 Regular Session

Oregon House Bill HB2513

Introduced
1/9/23  
Refer
1/11/23  
Report Pass
4/7/23  
Engrossed
4/13/23  
Refer
4/17/23  
Report Pass
6/15/23  
Enrolled
6/21/23  
Passed
7/13/23  
Chaptered
7/24/23  

Caption

Relating to drugs.

Impact

If passed, HB 2513 would significantly amend existing laws related to drug management at the state level. It aims to provide a solid legal groundwork for the regulation of new drug therapies while ensuring patient safety and compliance with federal guidelines. The legislation is positioned to bolster the state’s capability to combat issues like drug overdoses and prescription mismanagement by re-evaluating current practices surrounding drug distribution and access.

Summary

House Bill 2513 focuses on addressing issues related to drug regulation within the state. The bill aims to establish a more streamlined framework around the management, distribution, and oversight of pharmaceuticals and controlled substances. This legislation seeks to improve the efficiency of drug approval processes and enhance the state's ability to manage drug-related public health initiatives. By modernizing current regulations, the bill intends to ensure that health professionals can effectively respond to the evolving landscape of pharmaceuticals and healthcare delivery.

Sentiment

The sentiment surrounding HB 2513 appears to be generally positive, particularly among healthcare professionals and public health advocates who see its potential to enhance drug regulation and patient safety. However, some concerns have been raised regarding regulatory overreach and the possible implications for pharmaceutical companies, particularly concerning compliance costs and innovation. While many legislators express support, there are voices urging caution regarding implementation details.

Contention

Notable points of contention include concerns from stakeholders about the balance between regulation and innovation in the pharmaceutical industry. Some legislators worry that overly stringent rules could stifle the development of new treatments and medications. Furthermore, discussions around the bill have highlighted the importance of ensuring that regulations do not disproportionately affect smaller pharmaceutical companies and startups, which may struggle to meet more complex regulatory requirements.

Companion Bills

No companion bills found.

Previously Filed As

OR HB2481

Relating to behavioral health.

OR HB3094

Relating to drug treatment; prescribing an effective date.

OR SB881

Relating to substance use.

OR HB4002

Relating to the addiction crisis in this state; declaring an emergency.

OR HB4062

Relating to controlled substances; declaring an emergency.

OR SB1555

Relating to controlled substances; declaring an emergency.

OR SB1588

Relating to controlled substances.

OR SB610

Relating to funding for substance use services.

OR HB4036

Relating to controlled substances; prescribing an effective date.

OR HB2310

Relating to drugs; prescribing an effective date.

Similar Bills

CA SB1019

Youth mental health and substance use disorder services.

CA AB348

Full-service partnerships.

CA SB326

The Behavioral Health Services Act.

OR HB3094

Relating to drug treatment; prescribing an effective date.

DE HB160

An Act To Amend Title 16 Of The Delaware Code Relating To 988 Behavioral Health Crisis Intervention Services.

OR SB610

Relating to funding for substance use services.